Condition
MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Pf07275315 Dose 1
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 2/3 (1)
Trial Status
Active Not Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07363694Phase 2/3Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06981078Phase 2Active Not Recruiting
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Showing all 2 trials
Research Network
Common Treatments
- Pf07275315 Dose 11
- Verekitug1
- Pf07275315dose 21
- Pf07275315dose 31
Active Sponsors
- Pfizer Inc.1
- Upstream Bio Inc.1
- Pfizer1
Top Investigators
Upstream Bio
Related Conditions
- Chronic Obstructive Pulmonary Disease1
- Moderate To Severe Chronic Obstructive Pulmonary Disease1